The association between nuclear receptors and ocular diseases

Ke Liu _, Chang Zou and Bo Qin

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:27603-27615. https://doi.org/10.18632/oncotarget.15178

Metrics: PDF 1617 views  |   HTML 2413 views  |   ?  


Ke Liu1,2,*, Chang Zou3,* and Bo Qin2

1 Jinan University, Guangzhou, China

2 Shenzhen Eye Hospital, Affiliated Shenzhen Eye Hospital of Jinan University, Joint College of Optometry of Shenzhen University, Shenzhen Key Laboratory of Ophthalmology, Ocular Trauma Treatment and Stem Cell Differentiation Public Service Platform of Shenzhen, Shenzhen, China

3 Clinical Medical Research Center, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, China

* These authors have contributed equally to this work

Correspondence to:

Bo Qin, email:

Chang Zou, email:

Keywords: nuclear receptor, ocular disease

Received: November 02, 2016 Accepted: January 24, 2017 Published: February 07, 2017


Nuclear hormone receptors (NRs) are one of the most abundant transcription factors in the human cells. They regulate expression of genes via interactions with corresponding ligands, co-activators, and co-repressors. These molecular pathways play important roles in the development, cell differentiation, and physiologic and metabolic processes. Increasingly, targeting nuclear receptors is becoming a promising strategy for new drug development. The aim of this review is to discuss the association between nuclear receptors and eye development, and expand their role in various ocular diseases such as keratitis, cataract, glaucoma, uveitis, retinopathy, and ophthalmic tumors. Recent studies in this area are highlighted as well as future research directions and potential clinical applications. Finally, various strategies will be elucidated to inspire more targeted therapies for ocular diseases through the use of nuclear receptors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15178